Logo image of ELTX

ELICIO THERAPEUTICS INC (ELTX) Stock Fundamental Analysis

NASDAQ:ELTX - Nasdaq - US28657F1030 - Common Stock - Currency: USD

8.54  +0.44 (+5.43%)

After market: 8.96 +0.42 (+4.92%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ELTX. ELTX was compared to 572 industry peers in the Biotechnology industry. ELTX may be in some trouble as it scores bad on both profitability and health. ELTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ELTX has reported negative net income.
In the past year ELTX has reported a negative cash flow from operations.
ELTX had negative earnings in each of the past 5 years.
ELTX had a negative operating cash flow in each of the past 5 years.
ELTX Yearly Net Income VS EBIT VS OCF VS FCFELTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -245.49%, ELTX is not doing good in the industry: 92.54% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -245.49%
ROE N/A
ROIC N/A
ROA(3y)-86.57%
ROA(5y)-154.17%
ROE(3y)-155.03%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ELTX Yearly ROA, ROE, ROICELTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 200 -200 400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ELTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELTX Yearly Profit, Operating, Gross MarginsELTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K -2K -2.5K

More info and screens

0

2. Health

2.1 Basic Checks

ELTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ELTX has more shares outstanding
Compared to 5 years ago, ELTX has more shares outstanding
ELTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ELTX Yearly Shares OutstandingELTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
ELTX Yearly Total Debt VS Total AssetsELTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -19.51, we must say that ELTX is in the distress zone and has some risk of bankruptcy.
ELTX has a worse Altman-Z score (-19.51) than 86.15% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -19.51
ROIC/WACCN/A
WACC9.44%
ELTX Yearly LT Debt VS Equity VS FCFELTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 50M -50M

2.3 Liquidity

A Current Ratio of 0.88 indicates that ELTX may have some problems paying its short term obligations.
ELTX's Current ratio of 0.88 is on the low side compared to the rest of the industry. ELTX is outperformed by 89.88% of its industry peers.
ELTX has a Quick Ratio of 0.88. This is a bad value and indicates that ELTX is not financially healthy enough and could expect problems in meeting its short term obligations.
ELTX's Quick ratio of 0.88 is on the low side compared to the rest of the industry. ELTX is outperformed by 88.99% of its industry peers.
Industry RankSector Rank
Current Ratio 0.88
Quick Ratio 0.88
ELTX Yearly Current Assets VS Current LiabilitesELTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for ELTX have decreased strongly by -517.22% in the last year.
Looking at the last year, ELTX shows a very negative growth in Revenue. The Revenue has decreased by -91.88% in the last year.
Measured over the past years, ELTX shows a quite strong growth in Revenue. The Revenue has been growing by 15.57% on average per year.
EPS 1Y (TTM)-517.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.45%
Revenue 1Y (TTM)-91.88%
Revenue growth 3Y15.57%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.72% on average over the next years. This is quite good.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y56.91%
EPS Next 2Y30.01%
EPS Next 3Y20.91%
EPS Next 5Y13.72%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ELTX Yearly Revenue VS EstimatesELTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5M 10M 15M 20M 25M
ELTX Yearly EPS VS EstimatesELTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ELTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELTX Price Earnings VS Forward Price EarningsELTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELTX Per share dataELTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as ELTX's earnings are expected to grow with 20.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.01%
EPS Next 3Y20.91%

More info and screens

0

5. Dividend

5.1 Amount

ELTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELICIO THERAPEUTICS INC

NASDAQ:ELTX (2/21/2025, 8:15:37 PM)

After market: 8.96 +0.42 (+4.92%)

8.54

+0.44 (+5.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)03-27 2025-03-27/amc
Inst Owners9.42%
Inst Owner Change-91.32%
Ins Owners2.17%
Ins Owner Change19.46%
Market Cap102.91M
Analysts80
Price Target9.69 (13.47%)
Short Float %1.7%
Short Ratio3.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.6%
Min EPS beat(2)-3.44%
Max EPS beat(2)34.64%
EPS beat(4)1
Avg EPS beat(4)-35.75%
Min EPS beat(4)-118.56%
Max EPS beat(4)34.64%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-18.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.93
EYN/A
EPS(NY)-4
Fwd EYN/A
FCF(TTM)-3.01
FCFYN/A
OCF(TTM)-3
OCFYN/A
SpS0
BVpS-0.14
TBVpS-0.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -245.49%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-86.57%
ROA(5y)-154.17%
ROE(3y)-155.03%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.35%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.88
Quick Ratio 0.88
Altman-Z -19.51
F-Score4
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)146.5%
Cap/Depr(5y)191.9%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-517.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.45%
EPS Next Y56.91%
EPS Next 2Y30.01%
EPS Next 3Y20.91%
EPS Next 5Y13.72%
Revenue 1Y (TTM)-91.88%
Revenue growth 3Y15.57%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-60.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-48.56%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.44%
OCF growth 3YN/A
OCF growth 5YN/A